Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-29	SEK 0.4160	-0.12%	749,001
26-09-28	SEK 0.4165	-0.83%	1,568,268
26-09-25	SEK 0.4200	+1.33%	1,951,460
26-09-24	SEK 0.4145	-2.81%	805,079
26-09-23	SEK 0.4265	+6.09%	1,486,835

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 10:36:49 2026-09-29 EDT			5-day change	1st Jan Change
0.4160 ^SEK	-0.12%		+1.99%	-50.54%

09-24	Alzinova's Phase II Study to Be Presented at Alzheimer's Conference	FW
09-21	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program	CI

Market Cap	84.4M 8.48M 7.45M 7.05M 6.39M 12.01M 814M 12.08M 32.6M 415M 31.82M 31.13M 1.33B	P/E 2026 *	-1.54x	P/E 2027 *	-1.1x
Enterprise Value	68.4M 6.87M 6.04M 5.71M 5.18M 9.73M 659M 9.79M 26.42M 336M 25.79M 25.23M 1.08B	EV / Sales 2026 *	2.18x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Börse Stuttgart	78D	Delayed
Deutsche Boerse AG	78D	Delayed
CBOE		Real-time
CBOE		Real-time

09-24	Alzinova's Phase II Study to Be Presented at Alzheimer's Conference	FW
09-21	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program	CI
09-11	Stockholm stocks ended Friday higher	FW
09-11	Calendar Monday September 14 - Friday September 18	FW
09-11	Alzinova: Redeye cuts justified value to SEK 0.90	FW
09-11	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
09-11	Asker plunges on choppy Stockholm market	FW
09-11	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
09-11	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
09-11	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
09-10	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-24	Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference	AQ
09-22	The subscription period in Alzinovas rights issue of units starts today	AQ
09-21	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need	GL
09-18	Alzinova publishes information memorandum in connection with rights issue of units	AQ
09-11	Alzinova: Phase II study update and SEK51 rights issue	AQ

1 day	-1.56%
1 week	+1.99%
Current month	-48.75%
1 month	-48.75%
3 months	-23.93%
6 months	-31.32%
Current year	-50.54%

1 week	0.4	0.43
1 month	0.4	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	2015-08-31
Anders Waas BRD	Director/Board Member	69	2017-12-31
Carol Routledge BRD	Director/Board Member	-	2017-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-0.12%	+1.99%	-64.35%	-85.61%	8.48M
LONZA GROUP AG	-0.09%	+3.62%	+12.20%	+37.03%	49.06B
IQVIA HOLDINGS INC.	-1.51%	-1.16%	+47.72%	+35.68%	44.6B
REVOLUTION MEDICINES, INC.	-0.64%	+4.21%	+336.25%	+626.08%	43.24B
BEONE MEDICINES AG	-1.85%	-2.55%	+7.77%	+99.42%	41.73B
CELLTRION, INC.	+0.51%	-1.71%	+5.18%	+46.87%	29.93B
MEDPACE HOLDINGS, INC.	-0.26%	-2.19%	+23.09%	+154.56%	17.19B
TEMPUS AI, INC.	-1.38%	+8.96%	+7.05%	-	15.35B
EUROFINS SCIENTIFIC SE	-2.21%	-2.51%	+26.61%	+43.89%	15.54B
ASCENDIS PHARMA A/S	-2.38%	-5.71%	-	-	15.11B
Average	-1.18%	+1.35%	+44.61%	+119.74%	27.18B
Weighted average by Cap.	-0.97%	+2.26%	+72.72%	+163.16%

	2026 *	2027 *
Net sales	31.35M 3.15M 2.77M 2.62M 2.37M 4.46M 302M 4.49M 12.11M 154M 11.82M 11.56M 496M	-
Net income	-4.45M -447K -393K -372K -337K -633K -42.9M -637K -1.72M -21.89M -1.68M -1.64M -70.34M	-77M -7.73M -6.8M -6.43M -5.83M -10.95M -742M -11.02M -29.74M -379M -29.03M -28.4M -1.22B
Net Debt	-16M -1.61M -1.41M -1.34M -1.21M -2.28M -154M -2.29M -6.18M -78.7M -6.03M -5.9M -253M	-19M -1.91M -1.68M -1.59M -1.44M -2.7M -183M -2.72M -7.34M -93.46M -7.16M -7.01M -300M